Program
BI 3034701
A development code. Also written as “BI 3034701 (C-14)”, “BI3034701 formulation II” and “BI3034701 formulation C1”.
In Boehringer Ingelheim's pipeline, GLP-1/GIP/NPY2 receptor agonist
. Its studies are mostly in Obesity, led by Boehringer Ingelheim.
Furthest: phase 2, since Apr 30, 20266 company-led studies, 4 open or runningNext primary completion: Dec 15, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 64 open or running | phase 2since Apr 30, 2026 | Apr 3, 2024 | Dec 15, 2026phase 1 · NCT07837648 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 3034701
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2024First study: phase 1 study in HealthyFirst studyNCT06352437 · 125 enrolled · Germany
- Apr 30, 2026Phase 2 study in ObesityPhase 2 reachedNCT07662122 · 345 enrolled · United States, Australia, Canada and more
- Jul 3, 20262 phase 1 studiesNCT07693231, NCT07708493
- Aug 5, 2026Phase 1 study in OverweightNCT07754474 · 70 planned · Germany
- Sep 18, 2026Phase 1 study in HealthyNCT07837648 · 30 planned · United Kingdom
Ahead
- Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07837648
- Dec 22, 2026Primary completion: phase 1 study in ObesityNCT07693231
- Jun 21, 2027Primary completion: phase 1 study in OverweightNCT07754474
- Jun 26, 2027Primary completion: phase 2 study in ObesityNCT07662122
TargetBeta
“GLP-1/GIP/NPY2 receptor agonist”the company's pipeline, read by Claude · source
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07837648Healthy · United Kingdom | 1 | Recruiting | Dec 15, 2026 | 30 |
| NCT07754474Overweight · Germany | 1 | Recruiting | Jun 21, 2027 | 70 |
| NCT07708493Healthy · Hungary | 1 | Completed | Oct 29, 2026 | 8 |
| NCT07693231Obesity · Japan | 1 | Active, not recruiting | Dec 22, 2026 | 48 |
| NCT07662122Obesity · United States, Australia, Canada and more | 2 | Active, not recruiting | Jun 26, 2027 | 345 |
| NCT06352437Healthy · Germany | 1 | Completed | Oct 7, 2025 | 125 |
How it is read
Names in the registry
- “BI 3034701”, 4 entries
- “BI 3034701 (C-14)”, 1 entry
- “BI3034701 formulation II”, 1 entry
- “BI3034701 formulation C1”, 1 entry
Codes read as this program: BI3034701.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.